• Explore /
  • Poster
  • / Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Association of multiplex-immunofluorescence (m-IF) and gene expression signature with prognosis and bevacizumab (bev) treatment outcomes in NRG oncology/NSABP C-08: Implications for combining immune checkpoint blockade (ICB) and bev.

Abstract Poster

Authors

null

Katherine L. Pogue-Geile

NSABP/NRG Oncology, Pittsburgh, PA

Katherine L. Pogue-Geile , Marion E Joy , Ying Wang , Rim S Kim , Patrick G Gavin , Debora Fumagalli , Greg Yothers , Carmen Joseph Allegra , Ashok Srinivasan , Melanie Finnigan , Samuel A. Jacobs , Thomas J. George , Jennifer Marie Suga , Judith O. Hopkins , Naoyuki G. Saito , Norman Wolmark , Soonmyung Paik , Peter C. Lucas

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Translational Research

Clinical Trial Registration Number

00096278

DOI

10.1200/JCO.2022.40.4_suppl.140

Abstract #

140

Poster Bd #

G4

Abstract Disclosures

Similar Posters

First Author: Michael J. Overman

First Author: Caio Max Sao Pedro Rocha Lima

First Author: Caio Max Sao Pedro Rocha Lima

First Author: Michael J. Overman